Heart failure & cardiomyopathies
Efficacy and safety of human albumin combined with furosemide in acute decompensated heart failure with hepatic dysfunction
Authors' conclusion
In this hypothesis generating study, among patients with ADHF and hepatic dysfunction, concomitant use of IV albumin and furosemide for the first 72 hours resulted in a significant improvement in subjective perception symptoms of decongestion and a milder increase in creatinine levels than IV furosemide alone.
Study context
- Population
- Patients with hepatic dysfunction hospitalized for acute decompensated heart failure (ADHF)patients recruited (78 years, 54% female)
- Participants
- 241 patients
- Comparison
- Intravenous (IV) albumin with furosemide vs IV furosemide alone
- Primary endpoint
- Coprimary: patients' global assessment of symptoms score (AUC of visual analog scale score) and change in creatinine levels
- Follow-up
- 72 hours from admission
Primary result
As reported in the abstract
| Group | Global assessment of symptoms AUCbaseline-72 h | Increase in creatinine |
|---|---|---|
| IV albumin with furosemide | 3,767 points | 0.07 mg/dL |
| IV furosemide alone | 3,457 points | 0.18 mg/dL |
Global assessment of symptoms AUCbaseline-72 h
IV albumin with furosemide3,767 points
IV furosemide alone3,457 points
Increase in creatinine
IV albumin with furosemide0.07 mg/dL
IV furosemide alone0.18 mg/dL
Further findings
Length of stay
Incidence of worsening renal function
- Length of stay — 1 day shorter in the experimental treatment group
- P < .001
- Incidence of worsening renal function — Lower in the experimental treatment group
- P = .037
Original publication
Efficacy and safety of human albumin combined with furosemide in acute decompensated heart failure with hepatic dysfunction. Am Heart J. Published 3 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it